Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohammed Wael Al-Ameri

Pulmonary Disease Rochester Hills, MI Medical Doctor

NPI 1861591794 CMS profile 311200

75 Barclay Cir Ste 205, Ste 220, Rochester Hills, MI 48307

Open in the dashboard

General payments

$12,450

556 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohammed Wael Al-Ameri of Rochester Hills, MI is reported in the CMS Open Payments database as having received $12,450 across 556 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,598 115
2024 General $2,136 82
2023 General $2,337 87
2022 General $1,875 87
2021 General $1,393 75
2020 General $962 53
2019 General $1,149 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohammed Wael Al-Ameri
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Mohammed Wael Al-Ameri were reported at $2,598. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Mohammed Wael Al-Ameri Pulmonary Disease median Middle half National median
2019 $1,149 $377 $109–$1,340 $163
2020 $962 $230 $56–$907 $114
2021 $1,393 $269 $68–$1,072 $132
2022 $1,875 $390 $100–$1,457 $149
2023 $2,337 $419 $114–$1,659 $160
2024 $2,136 $476 $123–$1,818 $164
2025 $2,598 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,666 103 payments
  2. GlaxoSmithKline, LLC. $2,116 126 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,122 56 payments
  4. Genzyme Corporation $1,082 30 payments
  5. Actelion Pharmaceuticals US, Inc. $593 25 payments
  6. Regeneron Healthcare Solutions, Inc. $512 11 payments
  7. Insmed, Inc. $503 25 payments
  8. Mylan Specialty L.P. $455 27 payments
  9. United Therapeutics Corporation $424 12 payments
  10. Harmony Biosciences LLC $408 15 payments
  11. Other $2,568 126 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,275 553 payments
  2. Education $175 3 payments
Products named General payments · program years 2019–2025
  1. BREZTRI $1,169 40 payments
  2. DUPIXENT Immunology $1,149 29 payments
  3. TRELEGY ELLIPTA $1,006 73 payments
  4. AIRSUPRA $721 24 payments
  5. NUCALA $616 22 payments
  6. OFEV $558 23 payments
  7. OPSUMIT $554 23 payments
  8. Arikayce $503 25 payments
  9. DUPIXENT Inflammation And Immunology $485 10 payments
  10. UPTRAVI $451 17 payments
  11. Other $7,166 351 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

3,122

Median for Pulmonary Disease: 936

Drug cost

$1,448,228

Median for Pulmonary Disease: $487,987

Branded share of claims

63.5%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 696 $773,193
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 186 $196,028
Breo Ellipta Fluticasone/Vilanterol Brand 125 $96,635
Spiriva Respimat Tiotropium Bromide Brand 62 $66,846
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 43 $39,160
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 41 $35,954
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 54 $35,053
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 130 $32,864
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 52 $25,007
Advair Hfa Fluticasone Propion/Salmeterol Brand 34 $24,660

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$170,141

Medicare's payments for the services billed

Medicare patients

535

Average age 76

Services billed

3,425

331 women, 204 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 64%
Arthritis 56%
Ischemic heart disease 53%
Heart failure 39%
Atrial fibrillation 34%
Chronic kidney disease 33%
Diabetes 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $167
  • Regeneron Healthcare Solutions, Inc. $156
$323 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $307
$307 186 —
WAKIX
  • Harmony Biosciences LLC $218
$218 — —
Arikayce
  • Insmed, Inc. $187
$187 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $182
$182 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

556 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record